The majority of non-small-cell lung cancer (NSCLC) patients present with locally advanced (35%) or metastatic disease (40%); in this setting, it is of the utmost importance to balance efficacy with toxicity. However, with ...
[EN] Background: In advanced-stage (IIIB or IV) non-small-cell lung cancer (NSCLC), combination chemotherapy has demonstrated response rates of 20% and a 1-year survival rate of 30%. We conducted a multicentre, open-label, ...
Kerr, K. M.; Dafni, U.; Schulze, K.; Thunnissen, E.; Bubendorf, L.; Hager, H.; Finn, S.; Biernat, W.; Vliegen, L.; Losa, J. H.; Marchetti, A.; Cheney, R.; Warth, A.; Speel, E.-J.; Jantus-Lewintre, Eloisa(Oxford University Press, 2018)
[EN] Background
Reported prevalence of driver gene mutations in non-small-cell lung cancer (NSCLC) is highly variable and clinical correlations are emerging. Using NSCLC biomaterial and clinical data from the European ...